CAR T Cell Therapy: A New Hope for Autoimmune Diseases Beyond Cancer

Introduction

For decades, CAR T cell therapy has been celebrated as a breakthrough in cancer treatment, particularly for blood cancers like leukemia and lymphoma. But now, researchers are turning this powerful immunotherapy against a different enemy: autoimmune diseases. In a growing number of clinical trials, the same engineered immune cells that hunt and destroy tumors are being deployed to target the rogue cells responsible for conditions such as multiple sclerosis (MS), lupus, Graves' disease, and vasculitis. The goal is nothing less than a reset of the body's faulty immune system—potentially offering lasting relief for millions of patients who have exhausted conventional treatments.

What Is CAR T Cell Therapy?

CAR T—short for chimeric antigen receptor T cell therapy—is a personalized treatment that involves extracting a patient's own immune cells (T cells), genetically modifying them in a lab to recognize specific targets, and then infusing them back into the patient. In cancer, those targets are proteins on the surface of malignant cells. Once reinfused, the engineered T cells multiply and attack the cancer with remarkable precision.

The same principle applies to autoimmune diseases, but the targets are different: instead of tumor markers, the CAR T cells are programmed to seek out and eliminate the self-reactive B cells and T cells that drive the immune system to attack the body's own tissues. By wiping out these misdirected cells, the therapy aims to restore a healthy immune balance—effectively resetting the system to a pre-disease state.

One Patient's Journey: From MS to a Clinical Trial

At age 49, Jan Janisch-Hanzlik felt her multiple sclerosis slowly robbing her of independence. A former nurse, she had to switch from an active hospital role to a desk job because of her worsening symptoms. Frequent falls made her afraid to carry her grandchildren. Her home, once manageable, had to be enlarged to accommodate the wheelchair she feared she would soon need full-time.

Standard medications offered little improvement, and Janisch-Hanzlik worried her condition would only deteriorate. When she heard about a trial of CAR T cell therapy at the University of Nebraska Medical Center in Omaha—not far from her home in Blair—she took action. She called the clinic every other month until they were ready to enroll her as the first patient in the study. For her, the experimental treatment represented a last hope to halt the relentless progression of MS.

How CAR T Targets Autoimmune Diseases

In autoimmune conditions, the immune system mistakenly identifies healthy cells as threats. In MS, for instance, immune cells attack the protective myelin sheath around nerve fibers, leading to neurological damage. CAR T therapy can be designed to recognize and destroy the specific B cells that produce these self-attacking antibodies. By eliminating these troublemakers, the treatment may allow the immune system to regenerate a more tolerant repertoire—one that no longer attacks the body.

Early results from multiple trials are encouraging. Patients with lupus have seen dramatic reductions in disease activity, sometimes achieving remission after a single infusion. In Graves' disease, a form of hyperthyroidism caused by autoantibodies, CAR T cells have successfully reduced antibody levels and normalized thyroid function. Similar successes are being reported for vasculitis and other conditions.

Current Clinical Trials and Conditions Under Study

Hundreds of clinical trials worldwide are now exploring CAR T therapy for autoimmune diseases. The conditions being investigated include:

• Multiple sclerosis – targeting B cells that damage myelin
• Systemic lupus erythematosus – resetting the immune system to stop attacks on organs
• Graves' disease – eliminating thyroid-stimulating autoantibodies
• Vasculitis – stopping inflammation of blood vessels
• Type 1 diabetes – protecting insulin-producing cells
• Rheumatoid arthritis – reducing joint inflammation

Each trial uses slightly different CAR designs and target antigens, but the overarching goal remains the same: to achieve a durable remission without the need for lifelong immunosuppressive drugs.

Challenges and the Road Ahead

Despite the promise, CAR T therapy is not without risks. The most common side effects include cytokine release syndrome (a severe immune reaction) and neurological toxicities. However, many of these effects are manageable in a hospital setting. Another challenge is cost—current CAR T infusions for cancer can exceed $400,000, though prices may fall as the technology matures and competition increases.

Researchers are also working on off-the-shelf versions of CAR T cells that do not require a patient's own cells, which could lower costs and expand access. Meanwhile, the success in autoimmune diseases has drawn comparisons to a "reset button" for the immune system—a concept that was once theoretical but now seems increasingly attainable.

Conclusion

For patients like Jan Janisch-Hanzlik, CAR T cell therapy offers more than just a new treatment option—it offers a chance to reclaim the life that autoimmune disease stole. As clinical trials expand and early results accumulate, the therapy's potential to transform the landscape of autoimmune medicine grows clearer. If the success seen in blood cancers can be replicated in diseases like MS and lupus, CAR T may well become the revolutionary treatment that changes the story for millions.

To learn more about how CAR T works or read another patient's experience, explore the sections above.